Formaldehyde Dehydrogenase - Pipeline Review, H2 2019
Formaldehyde Dehydrogenase - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Formaldehyde Dehydrogenase - Pipeline Review, H2 2019'; Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) pipeline Target constitutes close to 5 molecules.
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Formaldehyde dehydrogenase (FDH) is a zinc-containing metalloenzyme that catalyzes the oxidation of formaldehyde to formate. Formaldehyde dehydrogenase decomposes S-nitrosoglutathione and indirectly regulates the level of cellular protein S-nitrosation. It plays important role in respiratory diseases such as asthma.
The report 'Formaldehyde Dehydrogenase - Pipeline Review, H2 2019' outlays comprehensive information on the Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 5 respectively. Report covers products from therapy areas Respiratory, Cardiovascular, Immunology, Gastrointestinal and Metabolic Disorders which include indications Inflammation, Crohn's Disease (Regional Enteritis), Diabetes, Idiopathic Pulmonary Fibrosis, Stroke, Asthma, Cardiac Arrest, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (Heart Failure), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Non-Alcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis.
SCOPE
SUMMARY
According to the recently published report 'Formaldehyde Dehydrogenase - Pipeline Review, H2 2019'; Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) pipeline Target constitutes close to 5 molecules.
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Formaldehyde dehydrogenase (FDH) is a zinc-containing metalloenzyme that catalyzes the oxidation of formaldehyde to formate. Formaldehyde dehydrogenase decomposes S-nitrosoglutathione and indirectly regulates the level of cellular protein S-nitrosation. It plays important role in respiratory diseases such as asthma.
The report 'Formaldehyde Dehydrogenase - Pipeline Review, H2 2019' outlays comprehensive information on the Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical stages are 5 respectively. Report covers products from therapy areas Respiratory, Cardiovascular, Immunology, Gastrointestinal and Metabolic Disorders which include indications Inflammation, Crohn's Disease (Regional Enteritis), Diabetes, Idiopathic Pulmonary Fibrosis, Stroke, Asthma, Cardiac Arrest, Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (Heart Failure), Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease), Non-Alcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46)
- The report reviews Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics and enlists all their major and minor projects
- The report assesses Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Overview
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Companies Involved in Therapeutics Development
Glenmark Pharmaceuticals Ltd
Saje Pharma LLC
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Drug Profiles
Small Molecule to Inhibit GSNOR for Chronic Obstructive Pulmonary Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPL-334 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPL-334.1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPL-850 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPL-891.1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Dormant Products
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Overview
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Companies Involved in Therapeutics Development
Glenmark Pharmaceuticals Ltd
Saje Pharma LLC
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Drug Profiles
Small Molecule to Inhibit GSNOR for Chronic Obstructive Pulmonary Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPL-334 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPL-334.1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPL-850 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SPL-891.1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Dormant Products
Formaldehyde Dehydrogenase (S Nitrosoglutathione Reductase or NAD Dependent Formaldehyde Dehydrogenase or EC 1.2.1.46) - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Glenmark Pharmaceuticals Ltd, H2 2019
Pipeline by Saje Pharma LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Glenmark Pharmaceuticals Ltd, H2 2019
Pipeline by Saje Pharma LLC, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
COMPANIES MENTIONED
Glenmark Pharmaceuticals Ltd
Saje Pharma LLC
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
COMPANIES MENTIONED
Glenmark Pharmaceuticals Ltd
Saje Pharma LLC
